The existence of a cardiomyopathy of obesity is supported by a range of evidence: epidemiologic study findings, which have shown an association between obesity and heart failure; ...

Obesity has an important influence on the development of heart failure, and is recognized as a risk factor for heart failure in the ACC/AHA heart failure guidelines. 1 Obesity cardiomyopathy ...

Potential Positives. Data published in a peer-reviewed journal support the efficacy of ZyVersa’s Inflammasome ASC Inhibitor IC 100 as a potential treatment for obesity-associated cardiomyopathy ...

Obesity cardiomyopathy (OCM) was identified as a distinct pathology associated with sudden cardiac death (SCD) based on records from a national referral center in the U.K. Autopsies showed that ...

We conducted the STEP-HFpEF DM (Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction and Diabetes Mellitus) trial, a double-blind, randomized ...

In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with ...

We conducted the Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial, a randomized ...

Semaglutide therapy in patients with obese heart failure leads to marked weight loss and notable gains in mood, function, and ...

ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate ...